Incyte (INCY) Cash from Operations (2010 - 2026)
Incyte posted quarterly Cash from Operations of 369351000.0 for Q1 2026, up 38.82% year-on-year from 266067000.0 in Q1 2025, and down 32.02% on a QoQ basis from 543301000.0 in Q4 2025.
Incyte (INCY) has 17 years of Cash from Operations data on file, last reported at 369351000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 38.82% year-over-year to 369351000.0; the trailing twelve-month figure through Mar 2026 stood at 1516782000.0 (up 296.45% YoY), and the FY2025 full-year result was 1413498000.0, up 321.52% from the prior year.
- Cash from Operations for Q1 2026 stood at 369351000.0, down from 543301000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 559389000.0 in Q3 2025 and bottomed at 575563000.0 in Q2 2024.
- The 5-year median for Cash from Operations is 266067000.0 (2025), against an average of 210859647.06.
- Peak annual rise in Cash from Operations reached 307.2% in 2024, while the deepest fall reached 287.77% in 2024.
- A 5-year view of Cash from Operations shows it stood at 283662000.0 in 2022, then sank by 47.92% to 147729000.0 in 2023, then soared by 158.05% to 381218000.0 in 2024, then soared by 42.52% to 543301000.0 in 2025, then plunged by 32.02% to 369351000.0 in 2026.
- The last three Cash from Operations figures came in at 369351000.0 (Q1 2026), 543301000.0 (Q4 2025), and 559389000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 369.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 369.35 Mn |
| Mar 31, 2026 | 369.35 Mn |
| Dec 31, 2025 | 543.30 Mn |
| Dec 31, 2025 | 543.30 Mn |
| Sep 30, 2025 | 559.39 Mn |
| Sep 30, 2025 | 559.39 Mn |
| Jun 30, 2025 | 44.74 Mn |
| Jun 30, 2025 | 44.74 Mn |
| Mar 31, 2025 | 266.07 Mn |
| Mar 31, 2025 | 266.07 Mn |
| Dec 31, 2024 | 381.22 Mn |
| Dec 31, 2024 | 381.22 Mn |
| Sep 30, 2024 | 310.87 Mn |
| Sep 30, 2024 | 310.87 Mn |
| Jun 30, 2024 | -575.56 Mn |
| Jun 30, 2024 | -575.56 Mn |
| Mar 31, 2024 | 218.81 Mn |
| Mar 31, 2024 | 218.81 Mn |
| Dec 31, 2023 | 147.73 Mn |
| Dec 31, 2023 | 147.73 Mn |
| Sep 30, 2023 | 147.84 Mn |
| Sep 30, 2023 | 147.84 Mn |
| Jun 30, 2023 | 306.53 Mn |
| Jun 30, 2023 | 306.53 Mn |
| Mar 31, 2023 | -105.60 Mn |
| Mar 31, 2023 | -105.60 Mn |
| Dec 31, 2022 | 283.66 Mn |
| Dec 31, 2022 | 283.66 Mn |
| Sep 30, 2022 | 296.38 Mn |
| Sep 30, 2022 | 296.38 Mn |
| Jun 30, 2022 | 174.16 Mn |
| Jun 30, 2022 | 174.16 Mn |
| Mar 31, 2022 | 215.74 Mn |
| Mar 31, 2022 | 215.74 Mn |
| Dec 31, 2021 | 115.35 Mn |
| Dec 31, 2021 | 115.35 Mn |
| Sep 30, 2021 | 255.10 Mn |
| Sep 30, 2021 | 255.10 Mn |
| Jun 30, 2021 | 172.94 Mn |
| Jun 30, 2021 | 172.94 Mn |
| Mar 31, 2021 | 206.10 Mn |
| Mar 31, 2021 | 206.10 Mn |
| Dec 31, 2020 | 107.32 Mn |
| Dec 31, 2020 | 107.32 Mn |
| Sep 30, 2020 | 182.12 Mn |
| Sep 30, 2020 | 182.12 Mn |
| Jun 30, 2020 | 269.38 Mn |
| Jun 30, 2020 | 269.38 Mn |
| Mar 31, 2020 | -683.42 Mn |
| Mar 31, 2020 | -683.42 Mn |
| Dec 31, 2019 | 131.62 Mn |
| Dec 31, 2019 | 131.62 Mn |
| Sep 30, 2019 | 270.42 Mn |
| Sep 30, 2019 | 270.42 Mn |
| Jun 30, 2019 | 152.96 Mn |
| Jun 30, 2019 | 152.96 Mn |
| Mar 31, 2019 | 155.66 Mn |
| Mar 31, 2019 | 155.66 Mn |
| Dec 31, 2018 | 83.84 Mn |
| Dec 31, 2018 | 83.84 Mn |
| Sep 30, 2018 | 199.15 Mn |
| Sep 30, 2018 | 199.15 Mn |
| Jun 30, 2018 | 32.40 Mn |
| Jun 30, 2018 | 32.40 Mn |
| Mar 31, 2018 | 20.84 Mn |
| Mar 31, 2018 | 20.84 Mn |
| Dec 31, 2017 | -89.27 Mn |
| Dec 31, 2017 | -89.27 Mn |
| Sep 30, 2017 | 53.12 Mn |
| Sep 30, 2017 | 53.12 Mn |
| Jun 30, 2017 | 116.79 Mn |
| Jun 30, 2017 | 116.79 Mn |
| Mar 31, 2017 | -173.64 Mn |
| Mar 31, 2017 | -173.64 Mn |
| Dec 31, 2016 | 94.38 Mn |
| Dec 31, 2016 | 94.38 Mn |
| Sep 30, 2016 | 95.27 Mn |
| Sep 30, 2016 | 95.27 Mn |
| Jun 30, 2016 | 17.57 Mn |
| Jun 30, 2016 | 17.57 Mn |
| Mar 31, 2016 | 97.54 Mn |
| Mar 31, 2016 | 97.54 Mn |
| Dec 31, 2015 | 72.88 Mn |
| Dec 31, 2015 | 72.88 Mn |
| Sep 30, 2015 | 7.72 Mn |
| Sep 30, 2015 | 7.72 Mn |
| Jun 30, 2015 | 13.39 Mn |
| Jun 30, 2015 | 13.39 Mn |
| Mar 31, 2015 | -4.59 Mn |
| Mar 31, 2015 | -4.59 Mn |
| Dec 31, 2014 | 44.72 Mn |
| Dec 31, 2014 | 44.72 Mn |
| Sep 30, 2014 | 27.79 Mn |
| Sep 30, 2014 | 27.79 Mn |
| Jun 30, 2014 | -14.56 Mn |
| Jun 30, 2014 | -14.56 Mn |
| Mar 31, 2014 | -31.69 Mn |
| Mar 31, 2014 | -31.69 Mn |
| Dec 31, 2013 | -11.69 Mn |
| Dec 31, 2013 | -11.69 Mn |
| Sep 30, 2013 | -11.95 Mn |
| Sep 30, 2013 | -11.95 Mn |
| Jun 30, 2013 | 8.08 Mn |
| Jun 30, 2013 | 8.08 Mn |
| Mar 31, 2013 | 24.74 Mn |
| Mar 31, 2013 | 24.74 Mn |
| Dec 31, 2012 | -22.01 Mn |
| Dec 31, 2012 | -22.01 Mn |
| Sep 30, 2012 | -27.15 Mn |
| Sep 30, 2012 | -27.15 Mn |
| Jun 30, 2012 | 8.72 Mn |
| Jun 30, 2012 | 8.72 Mn |
| Mar 31, 2012 | -54.40 Mn |
| Mar 31, 2012 | -54.40 Mn |
| Dec 31, 2011 | -39.78 Mn |
| Dec 31, 2011 | -39.78 Mn |
| Sep 30, 2011 | -46.98 Mn |
| Sep 30, 2011 | -46.98 Mn |
| Jun 30, 2011 | -30.74 Mn |
| Jun 30, 2011 | -30.74 Mn |
| Mar 31, 2011 | -44.22 Mn |
| Mar 31, 2011 | -44.22 Mn |
| Dec 31, 2010 | 27.40 Mn |
| Dec 31, 2010 | 27.40 Mn |
| Sep 30, 2010 | -29.52 Mn |
| Sep 30, 2010 | -29.52 Mn |
| Jun 30, 2010 | -2.77 Mn |
| Jun 30, 2010 | -2.77 Mn |
| Mar 31, 2010 | 102.82 Mn |
| Mar 31, 2010 | 102.82 Mn |